Breath Analysis Continuous Glucose Monitor BreathGlu Receives FDA Approval: Diabetic Patients Bid Farewell to Finger Pricks

AerBetics announced on January 14, 2029, that its breath analysis blood glucose monitor BreathGlu has received FDA Class II medical device approval. The device infers blood glucose levels by analyzing acetone and acetaldehyde concentration changes in exhaled breath, completely eliminating the need for blood sampling or sensor implantation.

BreathGlu resembles a small hair dryer; users blow into the device for 3 seconds to obtain a blood glucose reading. The device's built-in cavity ring-down spectroscopy (CRDS) sensor can detect volatile organic compound concentration changes at the ppb level, mapping them to blood glucose values through an AI model.

In clinical trials involving 2,400 diabetic patients, BreathGlu achieved 92.3% consistency with standard venous blood glucose testing, comparable to mainstream continuous glucose monitoring (CGM) device accuracy.

The device is priced at $299 with no consumables required. AerBetics CEO stated that BreathGlu's target users are Type 1 and Type 2 diabetic patients who need multiple daily blood glucose measurements but want to avoid the pain of finger pricks. With approximately 530 million diabetic patients globally, the market opportunity is enormous.